GROUP INSURANCE – HEALTH CLAIMS



C. P. 3950 Lévis (Québec) G6V 8C6 desjardinslifeinsurance.com/planmember 1-844-410-6485

PRIOR AUTHORIZATION REQUEST **ESBRIET (PIRFENIDONE) OFEV (NINTEDANIB)**

		PLEASE READ	THE INSTRUCTIO	NS ON TH	E LAST PAG	E OF THIS FO	RM.			
Α	PATIENT IDENTIFICATIO	ATIENT IDENTIFICATION (to be completed by the member)								
	Patient's last and first name			Relationship with mem		ber		Patient's date of birth	DD	
				🗌 Memb	er 🗌 Spo	ouse 🗌 Dep	endent child		DD	
	Member's last and first name				Contrac	Contract No. Co		ertificate No.		
	No., street, apt.		City			Pro	ovince	Postal o	ode	
						Trownice				
	Telephone Nos – Home: Office:			l	Extension: Email:		:			
	Since the response to this request includes confidential information, please indicate how you would like to be informed of the decision:									
	By mail (The response to your request will be sent to the address indicated in this section.) By fax:									
	Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.									
		Does the patient have drug co	verage under a private	e insurance p	olan?					
		Yes – Please provide a copy of the notice of approval or refusal. \rightarrow Copy attached to this form.								
	PRIVATE PLAN	Specify: Name of the insurer: .			Contra	act No.:		Certificate No.:		
		No								
		Has a request for reimbursem	ent been submitted u	nder your pr	ovincial plan?					
	PROVINCIAL PLAN	Yes – Please provide a copy	of the notice of appr	oval or refus	al. → 🗌	Copy attached	to this form.			
		No – Please explain:								
	PATIENT SUPPORT	Is the patient enrolled in a pat	ient support program	? Yes	No					
	PROGRAM	If so – Program name:								
_		Contact person:				elephone No.:		Extension:		
B1		THORIZATION FOR THE CO provided on the claim form is a								
	the information deemed nee and insurance companies; (k when necessary use the per	urposes of managing my file and s cessary to manage my file. The nc o) communicate to the said person sonal information it may have abo cerning my dependents, insofar a	on-exhaustive list of so ns or organizations on out me in existing files	ources from v ly the persor that are now	which information al information closed. This a	tion may be colle n about me that authorization is a	ected includes is deemed neo ilso valid for th	s healthcare professiona cessary for the purposes he collection, use and co	ls or facilities, of my file; (c)	
>	Signature of member: Date:									
	Last name and first name of parent/legal guardian (if applicable):									
	Signature of patient or parent/legal guardian (if applicable):				Date:					
B2	CONSENT TO THE COMMUNICATION OF PERSONAL INFORMATION TO A THIRD PARTY									
	physician's medical team of	im more efficiently, do you auth the reasons for the decision on y						attending physician or	the attending	
<	Yes No Signature of member:					Date: _				
	Last name and first name of parent/legal guardian (if applicable):									
	Signature of patient or parent/legal guardian (if applicable): Date:									
С		SECTION (to be completed by	y the attending physic							
	Physician's last and first nam	ne (PLEASE PRINT)		L	icense No.	3	pecialty			
	No., street, suite		City	City		Province		Postal c	ode	
	Telephone No.: Fax No.:									
>	Signature of physician:						Date:			
•	Drug name		Formulation	Strength	Dosage		S	cheduled duration of tr	eatment	
	Where is the drug administe	ered? 🗌 Home 🗌 Phy	sician's office	Private clinic	🗌 Hosp	ital – Inpatient	🗌 Hospita	al – Outpatient		
		Other (please specify):								
1	2509E (2024-04)	509E (2024-04) Desjardins Insurance refers to Desjardins Financial Security Life Assurance Company. Page 1 of 3								

C ATTENDING PHYSICIAN SECTION (continued)

 Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member. In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context. 					
DIAGNOSIS					
☐ Idiopathic pulmonary fibrosis ☐ Other therapeutic indication(s) – Pleas	e specify:	\Box Chronic fibrosing interstitial lung diseases with a progressive phenotype			
INFORMATION RELATING TO IDIOPAT	HIC PULMONARY FIBROSIS				
Forced vital capacity:% of the	predicted value				
Carbon monoxide lung diffusion capacity	(D _{LCO}) corrected for hemoglobin:	% of predicted value.			
Ratio of forced expiratory volume in 1 sec	ond to forced vital capacity (FEV1/FV	/C):			
INFORMATION RELATING TO CHRONIC	FIBROSING INTERSTITIAL LUNG E	DISEASES WITH A PROGRESSIVE PHENOTYPE			
Specify if the pulmonary fibrosis was co	firmed by:				
\Box High resolution CT scan		Other, please explain:			
Forced vital capacity:% of the	predicted value				
Carbon monoxide lung diffusion capacity (D _{LCO}) corrected for hemoglobin:% of predicted value.					
Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC):					
Please select one or more of the followin	g to explain progession of disease in t	the last 24 months:			
A decline in FVC, expressed as a percentage of the predicted value, of at least 10% in relative value					
A decline in FVC, expressed as a percentage of the predicted value, of 5% to less than 10% in relative value and a worsening of the pulmonary symptoms					
A decline in FVC, expressed as a percentage of the predicted value, of 5% to less than 10% in relative value and an increase in the extent of the fibrosis confirmed by CT scan					

A worsening of the pulmonary symptoms and an increase in the extent of the pulmonary fibrosis confirmed by CT scan

PRIOR MEDICATION OR TREATMENT

PRIOR MEDICATION OR TREATMENT		
Has the patient ever used medication or received treatment for this medical condition?	🗌 Yes	No

If not, please explain: _

If so, please list any medication already used or any treatment already received for this medical condition:

MEDICATION OR TREATMENT NAME	OUTCOME	TREATMENT PERIOD		
Name:	Inefficiency Intolerance Contraindication	From:		
Dose:	Specify:	YYYY MM DD		
Name:	Inefficiency Intolerance Contraindication	YYYY MM DD		
Dose:	Specify:	YYYY MM DD To:		
Name:	Inefficiency Intolerance Contraindication	From:		
Dose:	Specify:	YYYY MM DD To:		
Name:	Inefficiency Intolerance Contraindication	YYYY MM DD From:		
Dose:	Specify:	YYYY MM DD To:		

PRESCRIPTION RENEWAL

Forced vital capacity: ______% of the predicted value

D INSTRUCTIONS – HOW TO COMPLETE AND RETURN THIS FORM

1. Complete sections A and B.

4.

- 2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
- 3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

١.	Send form:	by fax:	Desjardins Insurance	by mail:	Desjardins Insurance
			Group Insurance, Health Claims,		Group Insurance, Health Claims
			418-838-2134 or 1-877-838-2134 (toll-free)		C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.